SavedAdd your journal

Journals / Türk Pediatri Arşivi / 2005 / Cilt: 40 - Sayı: 3

Ewing's sarcoma: results of single institute from Turkey, 1983-2003

Cerrahpaşa Tıp Fakültesi Ewing sarkom deneyimi: 1983-2003

Süheyla OCAK
Sergülen DERVİŞOĞLU
Murat HIZ
İnci YILDIZ
Ferda ÖZKAN
Hilmi APAK
Aylin CANPOLAT
Alp ÖZKAN
Tiraje CELKAN
Serap KARAMAN
Pages
232–234
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The 4-year event-free survival (EFS) and overall survival (OS) rates were 30.8 and 31.1 % respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to evaluate patients with Ewing's sarcoma treated at a single institute, retrospectively.
📊
Key Findings & Data:Material and Methods: 25 patients with Ewing's sarcoma admitted to Cerrahpaşa Faculty of Medicine Pediatric Hematology and Oncology Department between January 1983 and January 2003 were enrolled into the study.
💡
Conclusion & Impact:The 4-year event-free survival (EFS) and overall survival (OS) rates were 30.8 and 31.1 % respectively.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to evaluate patients with Ewing's sarcoma treated at a single institute, retrospectively. Material and Methods: 25 patients with Ewing's sarcoma admitted to Cerrahpaşa Faculty of Medicine Pediatric Hematology and Oncology Department between January 1983 and January 2003 were enrolled into the study. All patients were under age of 16 and had no treatment previously. All diagnoses were confirmed with biopsy. The survival rates were calculated by Kaplan-Meier method. Results: The median age was 9.0 years; range, 3.0 to 15.0 years. At diagnosis, 16 patients had local-regional disease, and 9 had distant metastases. The mean follow-up of all patients was 50 months (range 4-108 months). The 4-year event-free survival (EFS) and overall survival (OS) rates were 30.8 and 31.1 % respectively. Conclusion: Despite significant progress with the use of intensive multiagent chemotherapy and local control measures, satisfactory survival rates could not be achieved.

Özet

Amaç: Bu çalışmada kliniğimizde tek bir merkezde tedavi görmüş Ewing sarkom olguları geriye dönük olarak incelenmiştir. Gereç ve yöntem: Ocak 1983- Ocak 2003 yıllan arasında Cerrahpaşa Tıp Fakültesi Çocuk Hematoloji-Onkoloji bölümüne başvuran 16 yaş ve altı, daha önce tedavi görmemiş, biyopsi ile Ewing sarkom tanısı kesinleşmiş 25 olgu geriye dönük olarak incelenmiştir. Hastalarımızın sağkalım sonuçlan Kaplan-Meier yöntemine göre hesaplanmıştır. Bulgular: 25 Ewing sarkom olgunun ortanca yaşı 9 yaş, dağılım ise 3-15 yaş idi. Tanı anında 16'sında yerel tutulum 9'unda ise uzak yayılım mevcuttu. Ortalama 50 aylık izlem süresi (4-108 ay) sonucu 4 yıllık olaysız sağkalım ve toplam sağkahm süreleri sırası ile %3O,8 ve %31,1'dir. Çıkarım: Çok ilaçlı yoğun kemoterapi uygulamalanması ve yerel denetim yöntemlerinin gündeme girmesine rağmen sağkalım sonuçlarında istenen başarı sağlanamamıştır.

🔖

Cite This Article

OCAK, S., DERVİŞOĞLU, S., HIZ, M., YILDIZ, İ., ÖZKAN, F., APAK, H., CANPOLAT, A., ÖZKAN, A., CELKAN, T., KARAMAN, S. (2022). Ewing's sarcoma: results of single institute from Turkey, 1983-2003. Türk Pediatri Arşivi, Cilt: 40 - Sayı: 3, 232–234. https://ajindex.com/articles/641681

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ginsberg JP, Woo SY, Johnson ME, et al. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In Pizzo PA, Poplack DG (eds). Principles and Practice of Pediatric Oncology. 4rd ed. Philadelphia: J. B. Lippincott Company, 2002; 973- 1017
  2. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St. Jude Children's Research Hospital experience, 1979 1999. Cancer 2002; 94: 561- 9
  3. Donaldson S, Torrey M, Link M, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Int J Radiat Oncol Biol Phys 1998; 42: 125- 35
  4. Craft A, Cotterill S, Malcolm D, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The second United Kingdom children's cancer study group and the medical research council Ewing's tumor study. J Clin Oncol 1998;16:3628- 33
  5. Ahrens S, Hoffmann C, Jabar S, et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localised Ewing sarcoma of bone: The CESS 86 experience. Med Pediatr Oncol 1999; 32: 186- 95
  6. Rosito P, Mancini A, Rondelli R, et al. Italian cooperative study for the treatment of localised Ewing sarcoma of bone. Cancer 1999; 86: 421- 8
  7. Oberlin O, Bui B, Brunat-Mentigny M, et al. Prognostic factors in localised Ewing's sarcoma. An update of the EW88 study of the French Society of Pediatric Oncology. Med Pediatr Oncol 1996; 27: 259
  8. Wexler L, DeLaney T, Tsokos M, et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996; 78: 901- 11
  9. Cardenos-Cados R, Rivera-Luna R, Lopez-Facundo N, et al. Ewing's sarcoma: Prognosis and survival in Mexican children from a single institution. Ped Hematol Oncol 1999; 16: 519- 23
  10. Villarroel M, Tordecilla J, Salgado C, et al. Multimodal therapy for children and adolescents with Ewing's sarcoma: results of the first national Chilean trial (1986-1991). Med Pediatr Oncol 1997; 29: 190- 6
  11. Kutluk MT, Yalçın B, Akyüz C, Ruacan Ş, Büyükpamukçu M. Treatment results and prognostic factors in Ewing sarcoma. Pediatr Hematol Oncol 2004; 21: 597 610.